nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—Atenolol—Procarbazine—hematologic cancer	0.345	1	CrCrCtD
Betaxolol—CYP1A2—Anagrelide—hematologic cancer	0.0505	0.135	CbGbCtD
Betaxolol—CYP2D6—Lomustine—hematologic cancer	0.0268	0.0716	CbGbCtD
Betaxolol—CYP1A2—Carmustine—hematologic cancer	0.0265	0.0708	CbGbCtD
Betaxolol—CYP2D6—Idarubicin—hematologic cancer	0.0239	0.0638	CbGbCtD
Betaxolol—CYP1A2—Methoxsalen—hematologic cancer	0.0225	0.0602	CbGbCtD
Betaxolol—CYP1A2—Bortezomib—hematologic cancer	0.0214	0.0573	CbGbCtD
Betaxolol—CYP1A2—Daunorubicin—hematologic cancer	0.0205	0.0548	CbGbCtD
Betaxolol—CYP2D6—Hydroxyurea—hematologic cancer	0.0203	0.0542	CbGbCtD
Betaxolol—CYP1A2—Alitretinoin—hematologic cancer	0.0201	0.0537	CbGbCtD
Betaxolol—CYP1A2—Thalidomide—hematologic cancer	0.0187	0.0499	CbGbCtD
Betaxolol—CYP2D6—Bortezomib—hematologic cancer	0.0177	0.0472	CbGbCtD
Betaxolol—CYP1A2—Dacarbazine—hematologic cancer	0.0161	0.0429	CbGbCtD
Betaxolol—CYP1A2—Imatinib—hematologic cancer	0.0157	0.042	CbGbCtD
Betaxolol—CYP2D6—Imatinib—hematologic cancer	0.0129	0.0346	CbGbCtD
Betaxolol—CYP1A2—Dasatinib—hematologic cancer	0.0126	0.0337	CbGbCtD
Betaxolol—CYP2D6—Nilotinib—hematologic cancer	0.0118	0.0314	CbGbCtD
Betaxolol—CYP2D6—Vinorelbine—hematologic cancer	0.0117	0.0311	CbGbCtD
Betaxolol—CYP1A2—Etoposide—hematologic cancer	0.00786	0.021	CbGbCtD
Betaxolol—CYP2D6—Vinblastine—hematologic cancer	0.00719	0.0192	CbGbCtD
Betaxolol—CYP2D6—Dexamethasone—hematologic cancer	0.00532	0.0142	CbGbCtD
Betaxolol—CYP2D6—Doxorubicin—hematologic cancer	0.00442	0.0118	CbGbCtD
Betaxolol—Acebutolol—SLC22A1—hematologic cancer	0.000395	0.506	CrCbGaD
Betaxolol—Atenolol—ABCB1—hematologic cancer	0.000125	0.16	CrCbGaD
Betaxolol—Acebutolol—ABCB1—hematologic cancer	0.000115	0.147	CrCbGaD
Betaxolol—Metoprolol—ABCB1—hematologic cancer	9.7e-05	0.124	CrCbGaD
Betaxolol—Propranolol—ABCB1—hematologic cancer	4.9e-05	0.0627	CrCbGaD
Betaxolol—Fatigue—Dexamethasone—hematologic cancer	1.84e-05	7.38e-05	CcSEcCtD
Betaxolol—Fatigue—Betamethasone—hematologic cancer	1.84e-05	7.38e-05	CcSEcCtD
Betaxolol—Chills—Epirubicin—hematologic cancer	1.84e-05	7.36e-05	CcSEcCtD
Betaxolol—Pruritus—Etoposide—hematologic cancer	1.84e-05	7.36e-05	CcSEcCtD
Betaxolol—Shock—Prednisone—hematologic cancer	1.83e-05	7.33e-05	CcSEcCtD
Betaxolol—Arrhythmia—Epirubicin—hematologic cancer	1.83e-05	7.33e-05	CcSEcCtD
Betaxolol—Pain—Betamethasone—hematologic cancer	1.83e-05	7.32e-05	CcSEcCtD
Betaxolol—Pain—Dexamethasone—hematologic cancer	1.83e-05	7.32e-05	CcSEcCtD
Betaxolol—Visual impairment—Doxorubicin—hematologic cancer	1.83e-05	7.32e-05	CcSEcCtD
Betaxolol—Nervous system disorder—Prednisone—hematologic cancer	1.82e-05	7.31e-05	CcSEcCtD
Betaxolol—Tachycardia—Prednisone—hematologic cancer	1.82e-05	7.27e-05	CcSEcCtD
Betaxolol—Alopecia—Epirubicin—hematologic cancer	1.81e-05	7.25e-05	CcSEcCtD
Betaxolol—Skin disorder—Prednisone—hematologic cancer	1.81e-05	7.24e-05	CcSEcCtD
Betaxolol—Nausea—Gemcitabine—hematologic cancer	1.81e-05	7.23e-05	CcSEcCtD
Betaxolol—Vomiting—Cisplatin—hematologic cancer	1.8e-05	7.22e-05	CcSEcCtD
Betaxolol—Hyperhidrosis—Prednisone—hematologic cancer	1.8e-05	7.21e-05	CcSEcCtD
Betaxolol—Vision blurred—Methotrexate—hematologic cancer	1.8e-05	7.19e-05	CcSEcCtD
Betaxolol—Mental disorder—Epirubicin—hematologic cancer	1.79e-05	7.19e-05	CcSEcCtD
Betaxolol—Rash—Cisplatin—hematologic cancer	1.79e-05	7.16e-05	CcSEcCtD
Betaxolol—Dermatitis—Cisplatin—hematologic cancer	1.79e-05	7.15e-05	CcSEcCtD
Betaxolol—Malnutrition—Epirubicin—hematologic cancer	1.78e-05	7.14e-05	CcSEcCtD
Betaxolol—Erythema—Epirubicin—hematologic cancer	1.78e-05	7.14e-05	CcSEcCtD
Betaxolol—Diarrhoea—Etoposide—hematologic cancer	1.78e-05	7.11e-05	CcSEcCtD
Betaxolol—Anorexia—Prednisone—hematologic cancer	1.77e-05	7.1e-05	CcSEcCtD
Betaxolol—Eye disorder—Doxorubicin—hematologic cancer	1.77e-05	7.09e-05	CcSEcCtD
Betaxolol—Ill-defined disorder—Methotrexate—hematologic cancer	1.77e-05	7.08e-05	CcSEcCtD
Betaxolol—Tinnitus—Doxorubicin—hematologic cancer	1.77e-05	7.08e-05	CcSEcCtD
Betaxolol—Anaemia—Methotrexate—hematologic cancer	1.76e-05	7.05e-05	CcSEcCtD
Betaxolol—Feeling abnormal—Betamethasone—hematologic cancer	1.76e-05	7.05e-05	CcSEcCtD
Betaxolol—Feeling abnormal—Dexamethasone—hematologic cancer	1.76e-05	7.05e-05	CcSEcCtD
Betaxolol—Flushing—Doxorubicin—hematologic cancer	1.76e-05	7.05e-05	CcSEcCtD
Betaxolol—Cardiac disorder—Doxorubicin—hematologic cancer	1.76e-05	7.05e-05	CcSEcCtD
Betaxolol—Tension—Epirubicin—hematologic cancer	1.75e-05	7.01e-05	CcSEcCtD
Betaxolol—Dysgeusia—Epirubicin—hematologic cancer	1.75e-05	6.99e-05	CcSEcCtD
Betaxolol—Hypersensitivity—Triamcinolone—hematologic cancer	1.74e-05	6.95e-05	CcSEcCtD
Betaxolol—Nervousness—Epirubicin—hematologic cancer	1.73e-05	6.94e-05	CcSEcCtD
Betaxolol—Angiopathy—Doxorubicin—hematologic cancer	1.72e-05	6.89e-05	CcSEcCtD
Betaxolol—Malaise—Methotrexate—hematologic cancer	1.72e-05	6.88e-05	CcSEcCtD
Betaxolol—Dizziness—Etoposide—hematologic cancer	1.72e-05	6.88e-05	CcSEcCtD
Betaxolol—Muscle spasms—Epirubicin—hematologic cancer	1.71e-05	6.87e-05	CcSEcCtD
Betaxolol—Immune system disorder—Doxorubicin—hematologic cancer	1.71e-05	6.86e-05	CcSEcCtD
Betaxolol—Vertigo—Methotrexate—hematologic cancer	1.71e-05	6.86e-05	CcSEcCtD
Betaxolol—Mediastinal disorder—Doxorubicin—hematologic cancer	1.71e-05	6.84e-05	CcSEcCtD
Betaxolol—Chills—Doxorubicin—hematologic cancer	1.7e-05	6.81e-05	CcSEcCtD
Betaxolol—Urticaria—Dexamethasone—hematologic cancer	1.7e-05	6.8e-05	CcSEcCtD
Betaxolol—Urticaria—Betamethasone—hematologic cancer	1.7e-05	6.8e-05	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.7e-05	6.79e-05	CcSEcCtD
Betaxolol—Dizziness—Prednisolone—hematologic cancer	1.69e-05	6.78e-05	CcSEcCtD
Betaxolol—Arrhythmia—Doxorubicin—hematologic cancer	1.69e-05	6.78e-05	CcSEcCtD
Betaxolol—Asthenia—Triamcinolone—hematologic cancer	1.69e-05	6.77e-05	CcSEcCtD
Betaxolol—Body temperature increased—Betamethasone—hematologic cancer	1.69e-05	6.77e-05	CcSEcCtD
Betaxolol—Body temperature increased—Dexamethasone—hematologic cancer	1.69e-05	6.77e-05	CcSEcCtD
Betaxolol—Nausea—Cisplatin—hematologic cancer	1.68e-05	6.74e-05	CcSEcCtD
Betaxolol—Insomnia—Prednisone—hematologic cancer	1.68e-05	6.74e-05	CcSEcCtD
Betaxolol—Vision blurred—Epirubicin—hematologic cancer	1.68e-05	6.73e-05	CcSEcCtD
Betaxolol—Alopecia—Doxorubicin—hematologic cancer	1.67e-05	6.71e-05	CcSEcCtD
Betaxolol—Paraesthesia—Prednisone—hematologic cancer	1.67e-05	6.69e-05	CcSEcCtD
Betaxolol—Pruritus—Triamcinolone—hematologic cancer	1.67e-05	6.67e-05	CcSEcCtD
Betaxolol—Cough—Methotrexate—hematologic cancer	1.66e-05	6.66e-05	CcSEcCtD
Betaxolol—Mental disorder—Doxorubicin—hematologic cancer	1.66e-05	6.65e-05	CcSEcCtD
Betaxolol—Ill-defined disorder—Epirubicin—hematologic cancer	1.65e-05	6.63e-05	CcSEcCtD
Betaxolol—Vomiting—Etoposide—hematologic cancer	1.65e-05	6.61e-05	CcSEcCtD
Betaxolol—Erythema—Doxorubicin—hematologic cancer	1.65e-05	6.61e-05	CcSEcCtD
Betaxolol—Malnutrition—Doxorubicin—hematologic cancer	1.65e-05	6.61e-05	CcSEcCtD
Betaxolol—Anaemia—Epirubicin—hematologic cancer	1.65e-05	6.6e-05	CcSEcCtD
Betaxolol—Dyspepsia—Prednisone—hematologic cancer	1.64e-05	6.56e-05	CcSEcCtD
Betaxolol—Rash—Etoposide—hematologic cancer	1.64e-05	6.56e-05	CcSEcCtD
Betaxolol—Dermatitis—Etoposide—hematologic cancer	1.64e-05	6.55e-05	CcSEcCtD
Betaxolol—Headache—Etoposide—hematologic cancer	1.63e-05	6.51e-05	CcSEcCtD
Betaxolol—Chest pain—Methotrexate—hematologic cancer	1.62e-05	6.5e-05	CcSEcCtD
Betaxolol—Myalgia—Methotrexate—hematologic cancer	1.62e-05	6.5e-05	CcSEcCtD
Betaxolol—Arthralgia—Methotrexate—hematologic cancer	1.62e-05	6.5e-05	CcSEcCtD
Betaxolol—Tension—Doxorubicin—hematologic cancer	1.62e-05	6.49e-05	CcSEcCtD
Betaxolol—Decreased appetite—Prednisone—hematologic cancer	1.62e-05	6.48e-05	CcSEcCtD
Betaxolol—Dysgeusia—Doxorubicin—hematologic cancer	1.62e-05	6.47e-05	CcSEcCtD
Betaxolol—Rash—Prednisolone—hematologic cancer	1.61e-05	6.47e-05	CcSEcCtD
Betaxolol—Dermatitis—Prednisolone—hematologic cancer	1.61e-05	6.46e-05	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.61e-05	6.45e-05	CcSEcCtD
Betaxolol—Malaise—Epirubicin—hematologic cancer	1.61e-05	6.44e-05	CcSEcCtD
Betaxolol—Fatigue—Prednisone—hematologic cancer	1.6e-05	6.43e-05	CcSEcCtD
Betaxolol—Headache—Prednisolone—hematologic cancer	1.6e-05	6.43e-05	CcSEcCtD
Betaxolol—Discomfort—Methotrexate—hematologic cancer	1.6e-05	6.42e-05	CcSEcCtD
Betaxolol—Nervousness—Doxorubicin—hematologic cancer	1.6e-05	6.42e-05	CcSEcCtD
Betaxolol—Vertigo—Epirubicin—hematologic cancer	1.6e-05	6.42e-05	CcSEcCtD
Betaxolol—Syncope—Epirubicin—hematologic cancer	1.6e-05	6.41e-05	CcSEcCtD
Betaxolol—Constipation—Prednisone—hematologic cancer	1.59e-05	6.37e-05	CcSEcCtD
Betaxolol—Muscle spasms—Doxorubicin—hematologic cancer	1.59e-05	6.35e-05	CcSEcCtD
Betaxolol—Palpitations—Epirubicin—hematologic cancer	1.58e-05	6.31e-05	CcSEcCtD
Betaxolol—Confusional state—Methotrexate—hematologic cancer	1.57e-05	6.28e-05	CcSEcCtD
Betaxolol—Loss of consciousness—Epirubicin—hematologic cancer	1.57e-05	6.28e-05	CcSEcCtD
Betaxolol—Dizziness—Triamcinolone—hematologic cancer	1.56e-05	6.24e-05	CcSEcCtD
Betaxolol—Cough—Epirubicin—hematologic cancer	1.56e-05	6.23e-05	CcSEcCtD
Betaxolol—Vision blurred—Doxorubicin—hematologic cancer	1.56e-05	6.23e-05	CcSEcCtD
Betaxolol—Infection—Methotrexate—hematologic cancer	1.55e-05	6.19e-05	CcSEcCtD
Betaxolol—Nausea—Etoposide—hematologic cancer	1.54e-05	6.18e-05	CcSEcCtD
Betaxolol—Feeling abnormal—Prednisone—hematologic cancer	1.53e-05	6.14e-05	CcSEcCtD
Betaxolol—Asthenia—Betamethasone—hematologic cancer	1.53e-05	6.14e-05	CcSEcCtD
Betaxolol—Asthenia—Dexamethasone—hematologic cancer	1.53e-05	6.14e-05	CcSEcCtD
Betaxolol—Ill-defined disorder—Doxorubicin—hematologic cancer	1.53e-05	6.13e-05	CcSEcCtD
Betaxolol—Nervous system disorder—Methotrexate—hematologic cancer	1.53e-05	6.11e-05	CcSEcCtD
Betaxolol—Anaemia—Doxorubicin—hematologic cancer	1.53e-05	6.11e-05	CcSEcCtD
Betaxolol—Thrombocytopenia—Methotrexate—hematologic cancer	1.52e-05	6.1e-05	CcSEcCtD
Betaxolol—Nausea—Prednisolone—hematologic cancer	1.52e-05	6.09e-05	CcSEcCtD
Betaxolol—Myalgia—Epirubicin—hematologic cancer	1.52e-05	6.08e-05	CcSEcCtD
Betaxolol—Chest pain—Epirubicin—hematologic cancer	1.52e-05	6.08e-05	CcSEcCtD
Betaxolol—Arthralgia—Epirubicin—hematologic cancer	1.52e-05	6.08e-05	CcSEcCtD
Betaxolol—Anxiety—Epirubicin—hematologic cancer	1.51e-05	6.06e-05	CcSEcCtD
Betaxolol—Pruritus—Betamethasone—hematologic cancer	1.51e-05	6.05e-05	CcSEcCtD
Betaxolol—Pruritus—Dexamethasone—hematologic cancer	1.51e-05	6.05e-05	CcSEcCtD
Betaxolol—Skin disorder—Methotrexate—hematologic cancer	1.51e-05	6.05e-05	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.51e-05	6.04e-05	CcSEcCtD
Betaxolol—Hyperhidrosis—Methotrexate—hematologic cancer	1.5e-05	6.02e-05	CcSEcCtD
Betaxolol—Discomfort—Epirubicin—hematologic cancer	1.5e-05	6.01e-05	CcSEcCtD
Betaxolol—Vomiting—Triamcinolone—hematologic cancer	1.5e-05	6e-05	CcSEcCtD
Betaxolol—Malaise—Doxorubicin—hematologic cancer	1.49e-05	5.96e-05	CcSEcCtD
Betaxolol—Rash—Triamcinolone—hematologic cancer	1.48e-05	5.95e-05	CcSEcCtD
Betaxolol—Dry mouth—Epirubicin—hematologic cancer	1.48e-05	5.95e-05	CcSEcCtD
Betaxolol—Dermatitis—Triamcinolone—hematologic cancer	1.48e-05	5.94e-05	CcSEcCtD
Betaxolol—Vertigo—Doxorubicin—hematologic cancer	1.48e-05	5.94e-05	CcSEcCtD
Betaxolol—Anorexia—Methotrexate—hematologic cancer	1.48e-05	5.94e-05	CcSEcCtD
Betaxolol—Syncope—Doxorubicin—hematologic cancer	1.48e-05	5.93e-05	CcSEcCtD
Betaxolol—Urticaria—Prednisone—hematologic cancer	1.48e-05	5.92e-05	CcSEcCtD
Betaxolol—Headache—Triamcinolone—hematologic cancer	1.48e-05	5.91e-05	CcSEcCtD
Betaxolol—Body temperature increased—Prednisone—hematologic cancer	1.47e-05	5.89e-05	CcSEcCtD
Betaxolol—Confusional state—Epirubicin—hematologic cancer	1.47e-05	5.88e-05	CcSEcCtD
Betaxolol—Diarrhoea—Betamethasone—hematologic cancer	1.46e-05	5.86e-05	CcSEcCtD
Betaxolol—Diarrhoea—Dexamethasone—hematologic cancer	1.46e-05	5.86e-05	CcSEcCtD
Betaxolol—Palpitations—Doxorubicin—hematologic cancer	1.46e-05	5.84e-05	CcSEcCtD
Betaxolol—Oedema—Epirubicin—hematologic cancer	1.46e-05	5.83e-05	CcSEcCtD
Betaxolol—Hypotension—Methotrexate—hematologic cancer	1.45e-05	5.82e-05	CcSEcCtD
Betaxolol—Loss of consciousness—Doxorubicin—hematologic cancer	1.45e-05	5.81e-05	CcSEcCtD
Betaxolol—Infection—Epirubicin—hematologic cancer	1.45e-05	5.79e-05	CcSEcCtD
Betaxolol—Cough—Doxorubicin—hematologic cancer	1.44e-05	5.77e-05	CcSEcCtD
Betaxolol—Shock—Epirubicin—hematologic cancer	1.43e-05	5.73e-05	CcSEcCtD
Betaxolol—Nervous system disorder—Epirubicin—hematologic cancer	1.43e-05	5.72e-05	CcSEcCtD
Betaxolol—Thrombocytopenia—Epirubicin—hematologic cancer	1.43e-05	5.71e-05	CcSEcCtD
Betaxolol—Tachycardia—Epirubicin—hematologic cancer	1.42e-05	5.69e-05	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.42e-05	5.67e-05	CcSEcCtD
Betaxolol—Skin disorder—Epirubicin—hematologic cancer	1.41e-05	5.66e-05	CcSEcCtD
Betaxolol—Dizziness—Betamethasone—hematologic cancer	1.41e-05	5.66e-05	CcSEcCtD
Betaxolol—Dizziness—Dexamethasone—hematologic cancer	1.41e-05	5.66e-05	CcSEcCtD
Betaxolol—Hyperhidrosis—Epirubicin—hematologic cancer	1.41e-05	5.64e-05	CcSEcCtD
Betaxolol—Insomnia—Methotrexate—hematologic cancer	1.41e-05	5.63e-05	CcSEcCtD
Betaxolol—Chest pain—Doxorubicin—hematologic cancer	1.4e-05	5.63e-05	CcSEcCtD
Betaxolol—Myalgia—Doxorubicin—hematologic cancer	1.4e-05	5.63e-05	CcSEcCtD
Betaxolol—Arthralgia—Doxorubicin—hematologic cancer	1.4e-05	5.63e-05	CcSEcCtD
Betaxolol—Anxiety—Doxorubicin—hematologic cancer	1.4e-05	5.61e-05	CcSEcCtD
Betaxolol—Nausea—Triamcinolone—hematologic cancer	1.4e-05	5.6e-05	CcSEcCtD
Betaxolol—Paraesthesia—Methotrexate—hematologic cancer	1.4e-05	5.59e-05	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.4e-05	5.59e-05	CcSEcCtD
Betaxolol—Discomfort—Doxorubicin—hematologic cancer	1.39e-05	5.56e-05	CcSEcCtD
Betaxolol—Anorexia—Epirubicin—hematologic cancer	1.39e-05	5.56e-05	CcSEcCtD
Betaxolol—Dyspnoea—Methotrexate—hematologic cancer	1.39e-05	5.55e-05	CcSEcCtD
Betaxolol—Dry mouth—Doxorubicin—hematologic cancer	1.37e-05	5.5e-05	CcSEcCtD
Betaxolol—Hypersensitivity—Prednisone—hematologic cancer	1.37e-05	5.49e-05	CcSEcCtD
Betaxolol—Dyspepsia—Methotrexate—hematologic cancer	1.37e-05	5.48e-05	CcSEcCtD
Betaxolol—Hypotension—Epirubicin—hematologic cancer	1.36e-05	5.45e-05	CcSEcCtD
Betaxolol—Vomiting—Betamethasone—hematologic cancer	1.36e-05	5.44e-05	CcSEcCtD
Betaxolol—Vomiting—Dexamethasone—hematologic cancer	1.36e-05	5.44e-05	CcSEcCtD
Betaxolol—Confusional state—Doxorubicin—hematologic cancer	1.36e-05	5.44e-05	CcSEcCtD
Betaxolol—Decreased appetite—Methotrexate—hematologic cancer	1.35e-05	5.41e-05	CcSEcCtD
Betaxolol—Rash—Dexamethasone—hematologic cancer	1.35e-05	5.4e-05	CcSEcCtD
Betaxolol—Rash—Betamethasone—hematologic cancer	1.35e-05	5.4e-05	CcSEcCtD
Betaxolol—Oedema—Doxorubicin—hematologic cancer	1.35e-05	5.39e-05	CcSEcCtD
Betaxolol—Dermatitis—Dexamethasone—hematologic cancer	1.35e-05	5.39e-05	CcSEcCtD
Betaxolol—Dermatitis—Betamethasone—hematologic cancer	1.35e-05	5.39e-05	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.34e-05	5.38e-05	CcSEcCtD
Betaxolol—Fatigue—Methotrexate—hematologic cancer	1.34e-05	5.37e-05	CcSEcCtD
Betaxolol—Headache—Betamethasone—hematologic cancer	1.34e-05	5.36e-05	CcSEcCtD
Betaxolol—Headache—Dexamethasone—hematologic cancer	1.34e-05	5.36e-05	CcSEcCtD
Betaxolol—Infection—Doxorubicin—hematologic cancer	1.34e-05	5.36e-05	CcSEcCtD
Betaxolol—Asthenia—Prednisone—hematologic cancer	1.34e-05	5.35e-05	CcSEcCtD
Betaxolol—Pain—Methotrexate—hematologic cancer	1.33e-05	5.33e-05	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.33e-05	5.31e-05	CcSEcCtD
Betaxolol—Shock—Doxorubicin—hematologic cancer	1.32e-05	5.31e-05	CcSEcCtD
Betaxolol—Nervous system disorder—Doxorubicin—hematologic cancer	1.32e-05	5.29e-05	CcSEcCtD
Betaxolol—Thrombocytopenia—Doxorubicin—hematologic cancer	1.32e-05	5.28e-05	CcSEcCtD
Betaxolol—Pruritus—Prednisone—hematologic cancer	1.32e-05	5.27e-05	CcSEcCtD
Betaxolol—Insomnia—Epirubicin—hematologic cancer	1.32e-05	5.27e-05	CcSEcCtD
Betaxolol—Tachycardia—Doxorubicin—hematologic cancer	1.31e-05	5.26e-05	CcSEcCtD
Betaxolol—Skin disorder—Doxorubicin—hematologic cancer	1.31e-05	5.24e-05	CcSEcCtD
Betaxolol—Paraesthesia—Epirubicin—hematologic cancer	1.31e-05	5.23e-05	CcSEcCtD
Betaxolol—Hyperhidrosis—Doxorubicin—hematologic cancer	1.3e-05	5.21e-05	CcSEcCtD
Betaxolol—Dyspnoea—Epirubicin—hematologic cancer	1.3e-05	5.2e-05	CcSEcCtD
Betaxolol—Anorexia—Doxorubicin—hematologic cancer	1.28e-05	5.14e-05	CcSEcCtD
Betaxolol—Feeling abnormal—Methotrexate—hematologic cancer	1.28e-05	5.13e-05	CcSEcCtD
Betaxolol—Dyspepsia—Epirubicin—hematologic cancer	1.28e-05	5.13e-05	CcSEcCtD
Betaxolol—Diarrhoea—Prednisone—hematologic cancer	1.27e-05	5.1e-05	CcSEcCtD
Betaxolol—Nausea—Dexamethasone—hematologic cancer	1.27e-05	5.08e-05	CcSEcCtD
Betaxolol—Nausea—Betamethasone—hematologic cancer	1.27e-05	5.08e-05	CcSEcCtD
Betaxolol—Decreased appetite—Epirubicin—hematologic cancer	1.27e-05	5.07e-05	CcSEcCtD
Betaxolol—Hypotension—Doxorubicin—hematologic cancer	1.26e-05	5.04e-05	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.26e-05	5.03e-05	CcSEcCtD
Betaxolol—Fatigue—Epirubicin—hematologic cancer	1.25e-05	5.03e-05	CcSEcCtD
Betaxolol—Constipation—Epirubicin—hematologic cancer	1.24e-05	4.98e-05	CcSEcCtD
Betaxolol—Pain—Epirubicin—hematologic cancer	1.24e-05	4.98e-05	CcSEcCtD
Betaxolol—Urticaria—Methotrexate—hematologic cancer	1.24e-05	4.95e-05	CcSEcCtD
Betaxolol—Dizziness—Prednisone—hematologic cancer	1.23e-05	4.93e-05	CcSEcCtD
Betaxolol—Body temperature increased—Methotrexate—hematologic cancer	1.23e-05	4.92e-05	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.23e-05	4.91e-05	CcSEcCtD
Betaxolol—Insomnia—Doxorubicin—hematologic cancer	1.22e-05	4.88e-05	CcSEcCtD
Betaxolol—Paraesthesia—Doxorubicin—hematologic cancer	1.21e-05	4.84e-05	CcSEcCtD
Betaxolol—Dyspnoea—Doxorubicin—hematologic cancer	1.2e-05	4.81e-05	CcSEcCtD
Betaxolol—Feeling abnormal—Epirubicin—hematologic cancer	1.2e-05	4.8e-05	CcSEcCtD
Betaxolol—Dyspepsia—Doxorubicin—hematologic cancer	1.19e-05	4.75e-05	CcSEcCtD
Betaxolol—Vomiting—Prednisone—hematologic cancer	1.18e-05	4.74e-05	CcSEcCtD
Betaxolol—Rash—Prednisone—hematologic cancer	1.17e-05	4.7e-05	CcSEcCtD
Betaxolol—Dermatitis—Prednisone—hematologic cancer	1.17e-05	4.69e-05	CcSEcCtD
Betaxolol—Decreased appetite—Doxorubicin—hematologic cancer	1.17e-05	4.69e-05	CcSEcCtD
Betaxolol—Headache—Prednisone—hematologic cancer	1.17e-05	4.67e-05	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.16e-05	4.66e-05	CcSEcCtD
Betaxolol—Fatigue—Doxorubicin—hematologic cancer	1.16e-05	4.65e-05	CcSEcCtD
Betaxolol—Urticaria—Epirubicin—hematologic cancer	1.16e-05	4.63e-05	CcSEcCtD
Betaxolol—Constipation—Doxorubicin—hematologic cancer	1.15e-05	4.61e-05	CcSEcCtD
Betaxolol—Pain—Doxorubicin—hematologic cancer	1.15e-05	4.61e-05	CcSEcCtD
Betaxolol—Body temperature increased—Epirubicin—hematologic cancer	1.15e-05	4.61e-05	CcSEcCtD
Betaxolol—Hypersensitivity—Methotrexate—hematologic cancer	1.15e-05	4.59e-05	CcSEcCtD
Betaxolol—Asthenia—Methotrexate—hematologic cancer	1.12e-05	4.47e-05	CcSEcCtD
Betaxolol—Feeling abnormal—Doxorubicin—hematologic cancer	1.11e-05	4.44e-05	CcSEcCtD
Betaxolol—Nausea—Prednisone—hematologic cancer	1.11e-05	4.43e-05	CcSEcCtD
Betaxolol—Pruritus—Methotrexate—hematologic cancer	1.1e-05	4.41e-05	CcSEcCtD
Betaxolol—Hypersensitivity—Epirubicin—hematologic cancer	1.07e-05	4.29e-05	CcSEcCtD
Betaxolol—Urticaria—Doxorubicin—hematologic cancer	1.07e-05	4.28e-05	CcSEcCtD
Betaxolol—Body temperature increased—Doxorubicin—hematologic cancer	1.06e-05	4.26e-05	CcSEcCtD
Betaxolol—Diarrhoea—Methotrexate—hematologic cancer	1.06e-05	4.26e-05	CcSEcCtD
Betaxolol—Asthenia—Epirubicin—hematologic cancer	1.04e-05	4.18e-05	CcSEcCtD
Betaxolol—Pruritus—Epirubicin—hematologic cancer	1.03e-05	4.12e-05	CcSEcCtD
Betaxolol—Dizziness—Methotrexate—hematologic cancer	1.03e-05	4.12e-05	CcSEcCtD
Betaxolol—Diarrhoea—Epirubicin—hematologic cancer	9.96e-06	3.99e-05	CcSEcCtD
Betaxolol—Hypersensitivity—Doxorubicin—hematologic cancer	9.92e-06	3.97e-05	CcSEcCtD
Betaxolol—Vomiting—Methotrexate—hematologic cancer	9.89e-06	3.96e-05	CcSEcCtD
Betaxolol—Rash—Methotrexate—hematologic cancer	9.81e-06	3.93e-05	CcSEcCtD
Betaxolol—Dermatitis—Methotrexate—hematologic cancer	9.8e-06	3.92e-05	CcSEcCtD
Betaxolol—Headache—Methotrexate—hematologic cancer	9.74e-06	3.9e-05	CcSEcCtD
Betaxolol—Asthenia—Doxorubicin—hematologic cancer	9.66e-06	3.87e-05	CcSEcCtD
Betaxolol—Dizziness—Epirubicin—hematologic cancer	9.62e-06	3.85e-05	CcSEcCtD
Betaxolol—Pruritus—Doxorubicin—hematologic cancer	9.53e-06	3.82e-05	CcSEcCtD
Betaxolol—Vomiting—Epirubicin—hematologic cancer	9.25e-06	3.71e-05	CcSEcCtD
Betaxolol—Nausea—Methotrexate—hematologic cancer	9.24e-06	3.7e-05	CcSEcCtD
Betaxolol—Diarrhoea—Doxorubicin—hematologic cancer	9.21e-06	3.69e-05	CcSEcCtD
Betaxolol—Rash—Epirubicin—hematologic cancer	9.18e-06	3.68e-05	CcSEcCtD
Betaxolol—Dermatitis—Epirubicin—hematologic cancer	9.17e-06	3.67e-05	CcSEcCtD
Betaxolol—Headache—Epirubicin—hematologic cancer	9.12e-06	3.65e-05	CcSEcCtD
Betaxolol—Dizziness—Doxorubicin—hematologic cancer	8.91e-06	3.57e-05	CcSEcCtD
Betaxolol—Nausea—Epirubicin—hematologic cancer	8.65e-06	3.46e-05	CcSEcCtD
Betaxolol—Vomiting—Doxorubicin—hematologic cancer	8.56e-06	3.43e-05	CcSEcCtD
Betaxolol—Rash—Doxorubicin—hematologic cancer	8.49e-06	3.4e-05	CcSEcCtD
Betaxolol—Dermatitis—Doxorubicin—hematologic cancer	8.48e-06	3.4e-05	CcSEcCtD
Betaxolol—Headache—Doxorubicin—hematologic cancer	8.44e-06	3.38e-05	CcSEcCtD
Betaxolol—Nausea—Doxorubicin—hematologic cancer	8e-06	3.2e-05	CcSEcCtD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3R1—hematologic cancer	7.22e-06	0.000239	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—JAK2—hematologic cancer	7.17e-06	0.000238	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—UGT1A1—hematologic cancer	7.16e-06	0.000237	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	7.16e-06	0.000237	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—MAP2K1—hematologic cancer	7.14e-06	0.000237	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ARNTL—hematologic cancer	7.13e-06	0.000236	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—GRB2—hematologic cancer	7.11e-06	0.000235	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CD—hematologic cancer	7.1e-06	0.000235	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PDGFA—hematologic cancer	7.09e-06	0.000235	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—JAK2—hematologic cancer	7.01e-06	0.000232	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KITLG—hematologic cancer	6.99e-06	0.000231	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—MAP2K1—hematologic cancer	6.99e-06	0.000231	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—SLC22A1—hematologic cancer	6.97e-06	0.000231	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CRABP1—hematologic cancer	6.97e-06	0.000231	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—GRB2—hematologic cancer	6.95e-06	0.00023	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CD—hematologic cancer	6.94e-06	0.00023	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CA9—hematologic cancer	6.94e-06	0.00023	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ACP5—hematologic cancer	6.94e-06	0.00023	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PDGFA—hematologic cancer	6.93e-06	0.00023	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NCOR2—hematologic cancer	6.85e-06	0.000227	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KITLG—hematologic cancer	6.83e-06	0.000226	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—STAT5A—hematologic cancer	6.83e-06	0.000226	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CB—hematologic cancer	6.81e-06	0.000226	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ALOX5—hematologic cancer	6.79e-06	0.000225	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CDKN2B—hematologic cancer	6.77e-06	0.000224	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3R1—hematologic cancer	6.7e-06	0.000222	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—STAT5A—hematologic cancer	6.68e-06	0.000221	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CB—hematologic cancer	6.66e-06	0.000221	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CDKN2B—hematologic cancer	6.62e-06	0.000219	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NUP98—hematologic cancer	6.57e-06	0.000218	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3R1—hematologic cancer	6.55e-06	0.000217	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CD86—hematologic cancer	6.55e-06	0.000217	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—IDH1—hematologic cancer	6.53e-06	0.000216	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—JAK2—hematologic cancer	6.51e-06	0.000216	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HES1—hematologic cancer	6.46e-06	0.000214	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ABCC3—hematologic cancer	6.45e-06	0.000214	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—TXN—hematologic cancer	6.45e-06	0.000214	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTO1—hematologic cancer	6.45e-06	0.000214	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NCOR1—hematologic cancer	6.42e-06	0.000213	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CD86—hematologic cancer	6.4e-06	0.000212	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ADCY7—hematologic cancer	6.38e-06	0.000211	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NCOA3—hematologic cancer	6.38e-06	0.000211	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—JAK2—hematologic cancer	6.37e-06	0.000211	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FGF1—hematologic cancer	6.35e-06	0.00021	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CSF2—hematologic cancer	6.35e-06	0.00021	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NUP214—hematologic cancer	6.34e-06	0.00021	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HES1—hematologic cancer	6.32e-06	0.000209	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SPHK1—hematologic cancer	6.31e-06	0.000209	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NCOR1—hematologic cancer	6.28e-06	0.000208	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FOXO1—hematologic cancer	6.26e-06	0.000207	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—IL2—hematologic cancer	6.25e-06	0.000207	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PDGFRB—hematologic cancer	6.25e-06	0.000207	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CSF2—hematologic cancer	6.21e-06	0.000206	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FGF1—hematologic cancer	6.21e-06	0.000206	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—MTR—hematologic cancer	6.21e-06	0.000206	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ABCG2—hematologic cancer	6.21e-06	0.000206	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CB—hematologic cancer	6.18e-06	0.000205	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PDGFRA—hematologic cancer	6.15e-06	0.000204	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—JAK1—hematologic cancer	6.13e-06	0.000203	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PRKCG—hematologic cancer	6.13e-06	0.000203	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FOXO1—hematologic cancer	6.12e-06	0.000203	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—IL2—hematologic cancer	6.12e-06	0.000203	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PDGFRB—hematologic cancer	6.11e-06	0.000202	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ENO2—hematologic cancer	6.09e-06	0.000202	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—UGT1A1—hematologic cancer	6.07e-06	0.000201	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CB—hematologic cancer	6.05e-06	0.0002	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PDGFRA—hematologic cancer	6.01e-06	0.000199	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PRKCG—hematologic cancer	5.99e-06	0.000199	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—JAK1—hematologic cancer	5.99e-06	0.000199	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTT1—hematologic cancer	5.91e-06	0.000196	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SLC22A1—hematologic cancer	5.9e-06	0.000195	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CRABP1—hematologic cancer	5.9e-06	0.000195	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—SDC1—hematologic cancer	5.77e-06	0.000191	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ALOX5—hematologic cancer	5.75e-06	0.000191	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IL2RA—hematologic cancer	5.72e-06	0.00019	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—IL2—hematologic cancer	5.68e-06	0.000188	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TERT—hematologic cancer	5.66e-06	0.000187	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IL2RA—hematologic cancer	5.6e-06	0.000185	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NUP98—hematologic cancer	5.57e-06	0.000185	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—IL2—hematologic cancer	5.56e-06	0.000184	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TERT—hematologic cancer	5.54e-06	0.000183	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PDGFB—hematologic cancer	5.52e-06	0.000183	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ADCY7—hematologic cancer	5.41e-06	0.000179	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NCOA3—hematologic cancer	5.41e-06	0.000179	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PDGFB—hematologic cancer	5.4e-06	0.000179	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TSC2—hematologic cancer	5.4e-06	0.000179	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NUP214—hematologic cancer	5.37e-06	0.000178	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	5.31e-06	0.000176	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TSC2—hematologic cancer	5.28e-06	0.000175	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ABCG2—hematologic cancer	5.26e-06	0.000174	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—MTR—hematologic cancer	5.26e-06	0.000174	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FGFR3—hematologic cancer	5.19e-06	0.000172	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ENO2—hematologic cancer	5.16e-06	0.000171	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MAPK14—hematologic cancer	5.14e-06	0.00017	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FGFR3—hematologic cancer	5.08e-06	0.000168	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ESR1—hematologic cancer	5.04e-06	0.000167	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MAPK14—hematologic cancer	5.03e-06	0.000167	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTT1—hematologic cancer	5e-06	0.000166	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FN1—hematologic cancer	4.98e-06	0.000165	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ESR1—hematologic cancer	4.93e-06	0.000163	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	4.93e-06	0.000163	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—BAD—hematologic cancer	4.92e-06	0.000163	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NFKBIA—hematologic cancer	4.92e-06	0.000163	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NQO1—hematologic cancer	4.91e-06	0.000163	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CD44—hematologic cancer	4.91e-06	0.000163	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—SDC1—hematologic cancer	4.89e-06	0.000162	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NOTCH1—hematologic cancer	4.88e-06	0.000162	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FN1—hematologic cancer	4.87e-06	0.000161	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—BAD—hematologic cancer	4.82e-06	0.00016	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NFKBIA—hematologic cancer	4.82e-06	0.00016	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CD80—hematologic cancer	4.78e-06	0.000158	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NOTCH1—hematologic cancer	4.77e-06	0.000158	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CG—hematologic cancer	4.77e-06	0.000158	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KIT—hematologic cancer	4.77e-06	0.000158	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—NRAS—hematologic cancer	4.77e-06	0.000158	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PTPN11—hematologic cancer	4.68e-06	0.000155	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CD80—hematologic cancer	4.67e-06	0.000155	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	4.67e-06	0.000155	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	4.66e-06	0.000154	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KIT—hematologic cancer	4.66e-06	0.000154	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	4.66e-06	0.000154	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYCS—hematologic cancer	4.64e-06	0.000154	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	4.61e-06	0.000153	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	4.61e-06	0.000153	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	4.58e-06	0.000152	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—MAPK3—hematologic cancer	4.57e-06	0.000151	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CREB1—hematologic cancer	4.54e-06	0.00015	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—BRAF—hematologic cancer	4.48e-06	0.000148	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	4.47e-06	0.000148	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CCL2—hematologic cancer	4.44e-06	0.000147	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CREB1—hematologic cancer	4.44e-06	0.000147	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IL6R—hematologic cancer	4.43e-06	0.000147	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CREBBP—hematologic cancer	4.42e-06	0.000146	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	4.41e-06	0.000146	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—BRAF—hematologic cancer	4.38e-06	0.000145	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CCL2—hematologic cancer	4.34e-06	0.000144	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IL6R—hematologic cancer	4.33e-06	0.000143	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	4.32e-06	0.000143	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MAP2K1—hematologic cancer	4.22e-06	0.00014	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	4.19e-06	0.000139	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CD44—hematologic cancer	4.16e-06	0.000138	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NQO1—hematologic cancer	4.16e-06	0.000138	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	4.15e-06	0.000138	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	4.13e-06	0.000137	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	4.1e-06	0.000136	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	4.1e-06	0.000136	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTP1—hematologic cancer	4.09e-06	0.000136	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	4.07e-06	0.000135	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	4.06e-06	0.000135	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	4.01e-06	0.000133	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FGF2—hematologic cancer	4.01e-06	0.000133	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	3.96e-06	0.000131	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYCS—hematologic cancer	3.93e-06	0.00013	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FGF2—hematologic cancer	3.93e-06	0.00013	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	3.91e-06	0.000129	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ABCB1—hematologic cancer	3.87e-06	0.000128	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	3.87e-06	0.000128	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—JAK2—hematologic cancer	3.85e-06	0.000127	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	3.77e-06	0.000125	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—JAK2—hematologic cancer	3.76e-06	0.000125	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NCOR1—hematologic cancer	3.76e-06	0.000125	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTM1—hematologic cancer	3.76e-06	0.000125	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MDM2—hematologic cancer	3.75e-06	0.000124	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	3.69e-06	0.000122	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MDM2—hematologic cancer	3.67e-06	0.000122	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	3.65e-06	0.000121	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MTOR—hematologic cancer	3.65e-06	0.000121	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MTOR—hematologic cancer	3.57e-06	0.000118	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	3.57e-06	0.000118	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.52e-06	0.000117	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	3.49e-06	0.000116	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTP1—hematologic cancer	3.47e-06	0.000115	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	3.43e-06	0.000114	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	3.41e-06	0.000113	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	3.39e-06	0.000112	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CASP3—hematologic cancer	3.36e-06	0.000111	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.36e-06	0.000111	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IL2—hematologic cancer	3.36e-06	0.000111	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	3.35e-06	0.000111	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—IL6—hematologic cancer	3.34e-06	0.000111	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—MTHFR—hematologic cancer	3.32e-06	0.00011	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	3.32e-06	0.00011	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CASP3—hematologic cancer	3.29e-06	0.000109	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ABCB1—hematologic cancer	3.28e-06	0.000109	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IL2—hematologic cancer	3.28e-06	0.000109	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CCND1—hematologic cancer	3.27e-06	0.000108	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—IL6—hematologic cancer	3.27e-06	0.000108	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—JUN—hematologic cancer	3.26e-06	0.000108	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CCND1—hematologic cancer	3.2e-06	0.000106	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—JUN—hematologic cancer	3.19e-06	0.000106	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTM1—hematologic cancer	3.19e-06	0.000106	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NCOR1—hematologic cancer	3.19e-06	0.000106	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	3.16e-06	0.000105	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PTEN—hematologic cancer	3.16e-06	0.000105	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	3.1e-06	0.000103	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	3.09e-06	0.000102	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PTEN—hematologic cancer	3.09e-06	0.000102	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	3.08e-06	0.000102	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	3.02e-06	0.0001	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	3.01e-06	9.98e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EP300—hematologic cancer	3.01e-06	9.97e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EP300—hematologic cancer	2.95e-06	9.76e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SRC—hematologic cancer	2.93e-06	9.7e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SRC—hematologic cancer	2.86e-06	9.49e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	2.85e-06	9.45e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—STAT3—hematologic cancer	2.82e-06	9.35e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NRAS—hematologic cancer	2.82e-06	9.33e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—MTHFR—hematologic cancer	2.82e-06	9.33e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.79e-06	9.25e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	2.79e-06	9.24e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—STAT3—hematologic cancer	2.76e-06	9.15e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NRAS—hematologic cancer	2.76e-06	9.13e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	2.7e-06	8.94e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	2.64e-06	8.74e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MYC—hematologic cancer	2.62e-06	8.69e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	2.62e-06	8.67e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.59e-06	8.58e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MYC—hematologic cancer	2.57e-06	8.5e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	2.56e-06	8.48e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.48e-06	8.22e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.46e-06	8.13e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KRAS—hematologic cancer	2.42e-06	8.03e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ALB—hematologic cancer	2.42e-06	8.03e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KRAS—hematologic cancer	2.37e-06	7.86e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CG—hematologic cancer	2.37e-06	7.84e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.32e-06	7.68e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	2.23e-06	7.38e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CREBBP—hematologic cancer	2.19e-06	7.27e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	2.18e-06	7.22e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TP53—hematologic cancer	2.15e-06	7.14e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.14e-06	7.09e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TP53—hematologic cancer	2.11e-06	6.98e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CD—hematologic cancer	2.08e-06	6.89e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HRAS—hematologic cancer	2.06e-06	6.83e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ALB—hematologic cancer	2.05e-06	6.8e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HRAS—hematologic cancer	2.02e-06	6.68e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IL6—hematologic cancer	1.97e-06	6.53e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.96e-06	6.51e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IL6—hematologic cancer	1.93e-06	6.39e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PTEN—hematologic cancer	1.85e-06	6.13e-05	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—AKT1—hematologic cancer	1.82e-06	6.03e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.81e-06	6.01e-05	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—AKT1—hematologic cancer	1.78e-06	5.9e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—EP300—hematologic cancer	1.76e-06	5.84e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PTEN—hematologic cancer	1.57e-06	5.19e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—EP300—hematologic cancer	1.49e-06	4.95e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.3e-06	4.32e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CA—hematologic cancer	1.11e-06	3.66e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—AKT1—hematologic cancer	1.07e-06	3.53e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—AKT1—hematologic cancer	9.03e-07	2.99e-05	CbGpPWpGaD
